Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301354 | 0.83 | FAAH (0.54) | FAAHPKMHPGDHTTRAB9A | |
| SCHEMBL8139754 | 0.81 | KMO (0.48) | FAAHHPGDKDM4EHSD17B10SLC9A1 | |
| SCHEMBL19814651 | 0.80 | KMO (0.47) | FAAHHPGDKDM4EHSD17B10SLC9A1 | |
| SCHEMBL892926 | 0.78 | TUBB4A (0.59) | FAAHHPGDRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL25247852 | 0.77 | FAAH (0.63) | FAAHHPGDRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL12171394 | 0.77 | RAB9A (0.56) | FAAHPKMHPGDHTTRAB9A | |
| SCHEMBL1471974 | 0.77 | FAAH (1.00) | FAAH | |
| SCHEMBL4790263 | 0.76 | TUBB4A (0.57) | FAAHHPGDRAB9AKDM4ESMN1; SMN2 | |
| Lithium SCHEMBL30975782 | 0.76 | DHODH (0.42) | FAAHRAB9ANPC1GAA | |
| SCHEMBL29268908 | 0.76 | DHODH (0.42) | FAAHRAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | FAAH 3547/4885PKM 2387/4885HPGD 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.